Back to search results

Study of Messaging to Providers for Chronic Kidney Disease Treatment

This study is testing a new way to help doctors treat Chronic Kidney Disease (CKD) more effectively. It involves a "best practice alert" and "order set" that pops up on a doctor's computer screen when they open a patient's medical record. This alert reminds them about your CKD, shows your lab results, and suggests specific guideline-directed medical therapies (GDMT) that might be helpful. The goal is to see if this tool encourages doctors to prescribe these recommended treatments more often within 90 days. You might be eligible if you are 18 or older and have CKD, defined by specific eGFR (a measure of kidney function) and uACR (a measure of protein in urine) levels. The study aims to enroll 1000 participants.

Study design
This is a cluster-randomized clinical trial. Providers will be assigned to either receive the best practice alert or continue with usual care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your medical records will be reviewed for new GDMT prescriptions within 90 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07430930

Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Yale University
~1,000 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:Best practice alert and order set for CKD

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
New GDMT prescription within 90 days
Measured over Up to 90 days of randomization

Conditions

Chronic Kidney Diseases

Explore related trials

Chronic Kidney Disease

NCT07430930

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Yale New Haven Health

    New Haven, Connecticutno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Francis P Wilson, MD MSCE · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Francis P Wilson, MD MSCE
[email protected]
203-737-1704
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • New GDMT prescription within 90 daysUp to 90 days of randomization

    Proportion of patient subjects with one or more new eligible GDMT prescriptions within 90 days of randomization.